Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 372-380

  Molinsky, Jan ^a,b   Klanova, Magdalena ^a,b   Koc, Michal ^c   Beranova, Lenka ^c   Andera, Ladislav ^c   Ludvikova, Zdenka ^d   Bohmova, Martina ^d   Gasova, Zdenka ^d   Strnad, Miroslav ^e   Ivanek, Robert ^f   Trneny, Marek ^b,d   Necas, Emanuel ^a   Zivny, Jan ^a   Klener, Pavel ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^e PALACKÝ UNIVERSITY   (Czech Republic)

^f Charles University in Prague and General University Hospital in Prague   (Czech Republic)

Author keywords

Apoptosis; Leukemia; Lymphoma; Roscovitine; Synergism; TRAIL

Indexed keywords

CASPASE; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ROSCOVITINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; FAS LIGAND PROTEIN; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MITOCHONDRIA; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872030780     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.710331     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, anew member of the tumor necrosis factor cytokine family. JBiol Chem 1996; 271: 12687-12690.
3. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
4. Sprick MR, Rieser E, Stahl H, et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in aFADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002; 21: 4520-4530.
5. Scaffidi C, Fulda S, Srinivasan S, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
6. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
7. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. JClin Invest 1999; 104: 155-162.
8. Testa U. TRAIL/TRAIL-R in hematologic malignancies. JCell Biochem 2010; 110: 21-34.
9. Kim EH, Kim SU, Shin DY, et al. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004; 23: 446-456.
10. Ortiz-Ferron G, Yerbes R, Eramo A, et al. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through apleiotropic mechanism. Cell Res 2008; 18: 664-676.
11. Festa M, Petrella A, Alfano S, et al. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-B pathway. Int JCancer 2009; 124: 2728-2736.
12. Azevedo WF, Leclerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur JBiochem 1997; 243: 518-526.
13. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. JBiol Chem 2005; 280: 31208-31219.
14. Alvi AJ, Austen B, Weston VJ, et al. Anovel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005; 105: 4484-4491.
15. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and downregulation of Mcl-1. Cancer Res 2005; 65: 5399-5407.
16. Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16: 1169-1176.
17. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18: 747-755.
18. Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma 2007; 48: 158-167.
19. Havlice kL, Hanus J, Vesely J, et al. Cytokinin-derived cyclindependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. JMed Chem 1997; 40: 408-412.
20. Oikonomou E, Koc M, Sourkova V, et al. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011; 6: e21632.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: apractical and powerful approach to multiple testing. JR Stat Soc B 1995; 57: 289-300.
22. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008; 4; 44-57.
23. Jin Z, Li Y, Pitti R, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009; 137: 721-735.
24. Ljungman M, Paulsen MT. Thecyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60: 785-789.
25. Garrof é-Ochoa X, Cosialls A, Ribas J, et al. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds. Apoptosis 2011; 16: 660-670.
26. Certo M, Moore VDG, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
27. Deng J, Carlson N, Takeyama K, et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-185.
28. Meng XW, Lee S-H, Dai H, et al. MCL-1 as abuffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis. JBiol Chem 2007; 282: 29831-29846.